Filing Flows › Alamar Biosciences (ALMR) › Q2 2026 › vs Q2 2025
Alamar Biosciences (ALMR) Q2 2026 vs Q2 2025 (year over year)
Alamar Biosciences's revenue rose $13.3M (+82%) from $16.2M in Q2 2025 to $29.4M in Q2 2026. The biggest changes: Product +$11.2M (+93%); Service Other +$2.0M (+49%).
Alamar Biosciences, Q2 2026: revenue $29.4M (+82% year over year), operating margin -46.0%, net loss $13.2M, operating cash flow −$11.3M. The chart draws each line against Q2 2025, the increases inside each band.
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| Consumables | $15.5M | $6.3M | $9.2M | +147% |
| Instruments | $7.8M | $5.8M | $2.0M | +35% |
| Product | $23.3M | $12.0M | $11.2M | +93% |
| Service Other | $6.2M | $4.1M | $2.0M | +49% |
| Revenue | $29.4M | $16.2M | $13.3M | +82% |
| Other income, net | $240K | $896K | −$656K | -73% |
| Income tax benefit | $93K | $0 | $93K | — |
| Net loss | $13.2M | $7.0M | $6.2M | +88% |
| Costs & expenses | $43.0M | $24.1M | $18.9M | +78% |
| Operating costs | $43.0M | $24.1M | $18.9M | +78% |
| Cost of revenue | $11.7M | $7.6M | $4.1M | +54% |
| Research & development | $13.8M | $8.9M | $4.9M | +55% |
| SG&A | $17.4M | $7.6M | $9.8M | +129% |
| Operating cash sources | $15.7M | $13.5M | $2.3M | +17% |
| Depreciation & amortization | $1.1M | $919K | $215K | +23% |
| Share-based compensation | $3.3M | $680K | $2.6M | +382% |
| Cash used in operations | $11.3M | $11.9M | −$560K | -5% |
| Net loss absorbed | $13.2M | $7.0M | $6.2M | +88% |
| Working capital & other | $2.5M | $6.5M | −$3.9M | -61% |
Questions
How much did Alamar Biosciences's revenue grow year over year in Q2 2026?
Alamar Biosciences's revenue rose $13.3M (+82%) from $16.2M in Q2 2025 to $29.4M in Q2 2026.
What drove Alamar Biosciences's revenue change in Q2 2026?
Product +$11.2M (+93%); Service Other +$2.0M (+49%).